Collaborators seek parasite invasion blockers

NewsGuard 100/100 Score

A malaria research team, including WEHI Structural Biologist, Professor Ray Norton, has received a US$1 million grant from the US National Institutes of Health to develop more effective malaria treatments.

Together with Professor Robin Anders and Associate Professor Mick Foley from La Trobe University’s Department of Biochemistry, Professor Norton will investigate the structure and function of two malaria proteins, their implications for the disease and induced immunological responses.

More specifically, the group hopes to identify which parts of these key antigen molecules are recognised by antibodies that are activated in the immune response to malaria infection. They are particularly interested in those parts of the molecules that bind to antibodies that block parasite invasion.

One of the main reasons that the most lethal malaria parasite, Plasmodium falciparum, has proven such a formidable foe is its multi-faceted ability to largely evade the body’s immunological response.

The group believes that identifying the most potentially effective elements of the immune response against these proteins on the malaria surface will help to improve their properties as vaccine candidates.

Of particular interest to Professor Norton is the application of such new knowledge to help head off the capability of the parasite to invade healthy red blood cells.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer